Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
РУДН, Москва
• эффективен при терапии шизофрении, протекающей с аффективными колебаниями, постпсихотических депрессий и шизоаффективного психоза; • эффективен и утвержден для лечения как маниакальной (моно- или комбинированная терапия), так и депрессивной фазы (монотерапия) БАР; • эффективен при лечении БАР с быстрой сменой фаз; • характеризуется широким клинико-фармакологическим спектром (наличие антиманиакального/антипсихотического, антиагрессивного, антидепрессивного, анксиолитического и седативного эффектов) и быстрым наступлением клинического эффекта (редукции маниакальной симптоматики уже на 1-й неделе); • не уступает по своей эффективности такому классическому антипсихотику, как галоперидол, но выгодно отличается от него отсутствием побочных экстрапирамидных эффектов и отсутствуем длительного повышения уровня пролактина; • хорошо сочетается с препаратами лития, вальпроатами; • позволяет отказаться от сопутствующего применения бензодиазепинов; • имеет хороший профиль безопасности.
Список исп. литературыСкрыть список 1. Бурлаков В.А. К проблеме лечения шизофрении, протекающей с сенестоипохондрическими нарушениями (опыт применения Сероквеля). Психиат. и психофармакотер. 2003; 2: 106–9. 2. Бурчинский С.Г. Нейролептики в фармакотерапии биполярных аффективных расстройств: возможности выбора. Нейро News: психоневрология и нейропсихиатрия. 2009; 6: http: //neuro.health-ua.com/article/203.html 3. Гурович И.Я., Шмуклер А.Б., Магомедова М.В. и др. Помощь больным шизофренией с первыми психотическими эпизодами: применение кветиапина. Соц. и клин. психиат. 2004; 3: 69–72. 4. Иванов М.В., Мазо Г.Э., Чомский А.Н. и др. Сероквель: перспективы и опыт терапии маний при биполярных аффективных расстройствах. Обоз. психиат. и мед. психол. им. В.М.Бехтерева. 2004; 4: 15–7. 5. Ильина Н.А. Терапия шизофрении и шизоаффективных расстройств: опыт применения кветиапина (сероквеля). Психиат. и психофармакотер. 2004; 6: 276–82. 6. Калинин В.В. Применение препарата Сероквель (кветиапин) для лечения больных шизофренией. Психиат. и психофармакотер. 2005; 2: 34–8. 7. Калинин В.В. Сероквель – атипичный нейролептик: особенности психотропного эффекта и показания. Психиат. и психофармакотер. 2001; 5. 8. Любов Е.Б., Чапурин С.А., Чурилин Ю.Ю. Фармакоэкономическая модель антирецидивного лечения Сероквелем, Рисполептом и Зипрексой пациентов в первом эпизоде шизофрении. Психиат. и психофармакотер. 2005; 4: 193–8. 9. Мазо Г.Э. Влияние терапии Сероквелем на депрессивную симптоматику в структуре шизофрении. Психиат. и психофармакотер. 2003; 6: 259–62. 10. Малин Д.И. Место нейролептической терапии в лечении биполярного аффективного расстройства. 2004; 5: 236–8. 11. Малин Д.И. Эффективность кветиапина (сероквеля) в лечении острых психозов при адекватном дозировании. Психиат. и психофармакотер. 2005; 3: 149–51. 12. Мосолов С.Н. Полвека нейролептической терапии: основные итоги и новые рубежи. Новые достижения в терапии психических заболеваний. М., 2002. 13. Мосолов С.Н., Александровский Ю.А., Вовин Р.Я. и др. Новый атипичный антипсихотик Сероквель. Результаты российских клинических испытаний. Психиат. и психофармакотер. 1999; 2: 16–24. 14. Смулевич А.Б., Зеленина Е.В. Терапия маниакальных и маниакально-бредовых состояний (клинические эффекты Сероквеля). Психиат. и психофармакотер. 2005; 1: 20–4. 15. Ястребов Д.В. Клиническое применение препарата сероквель. Фарматека. Неврология, Психиатрия. 2005; 17 (112): 112. 16. Ahlfors UG, Baastrup PC, Dencker SJ et al. Flupenthixol decanoate in recurrent manic-depressive illness. A comparison with lithium. Acta Psychiat Scand 1981; 64 (3): 226–37. 17. Altshuler LL, Gitlin MJ, Mintz J et al. Subsyndromal depression is associated with functional impairment in patients with bipolar disorder. J Clin Psychiat 2002; 63: 807–81. 18. American Psychiatric Association: Practice Guideline for the Treatment of Patients With Bipolar Disorder (Revision). Am J Psychiat 2002; 159. 19. Apter JT, Cantillon M. Efficacy, safety, and tolerability of \'Seroquel\' (quetiapine fumarate) in elderly patients with psychotic disorders. Abstracts of the 36th Annual Meeting of the American College of Neuropsychopharmacology. 1997; p. 295. 20. Arango C, Bobes J. Managing acute exacerbation of schizophrenia: focus on quetiapine. Curr Med Res Opin 2004; 5: 19–26. 21. Arvanitis LA, Miller BG. the Seroquel Trial 13 study group. Multiple fixed doses of \'Seroquel\' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiat 1997; 42: 233–46. 22. Avnon M, Goldin V, Neissburg J. Two long-term neuroleptic resistant patients treated by "Seroquel" (JCJ 204636) an atypical neuroleptic. Eur Neuropsychopharmacol 1996; 6: 54–124. 23. Audinot V, Canton H, Newman-Tancredi A et al. In vitro and ex vitro patterns of occupation of 5-HT2A and a1-adrenergic as compared to dopamine D2-receptors by novel antypsychotics. Eur Neuropsychopharmacol 1995; 3: 330. 24. Bartko G, Varadi H, Simon L et al. Patient satisfaction after switching from conventional to new atypical antipsychotics in schizophrenia. Int J Psychiat Clin Pract 2002; 6: 9–14. 25. Brecher MM, Huizar K. Quetiapine monotherapy for acute mania with bipolar disorder. Presented at the 27th Nordic Psychiatric Congress, August 13–16, 2003, Reykjavik, Iceland. 26. Bobes J, Garcia-Portilla MP, Saiz PA et al. High degree of tolerability for monotherapy with high doses of quetiapine: a case report. J Clin Psychiat 2002; 63: 1048–9. 27. Calabrese JR, Bowden CL, Sachs GS et al. A double-blind placebocontrolled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiat 1999; 60: 79–88. 28. Calabrese JR, Keck PE, Macfadden W et al. A Randomized, Double-Blind, Placebo-Controlled Trial of Quetiapine in the Treatment of Bipolar I or II Depression. Am J Psychiat 2005; 162: 1351–60. 29. Casey D. Seroquel (quetiapine): preclinical and clinical findings of a new atypical antipsychotic. Exp Opin Invest Drugs 1996; 8: 939–57. 30. Chengappa KNR, Goldstein JM, Greenwood M et al. A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clin Ther 2003; 25: 530–41. 31. Chengappa KNR, Parepally H, Brar JS et al. A random- assignment, double-blind, clinical trial of once- vs twice-daily administration of quetiapine fumarate in patients with schizophrenia or schizoaffective disorder: a pilot study. Can J Psychiat 2003; 48: 187–94. 32. Copolov DL, Link CGG, Kowalcyk B. A multicentre, double- blind, randomized comparison of quetiapine (ICI 204, 636, "Seroquel") and haloperidol in schizophrenia. Psychol Med 2000; 30: 95–105. 33. DelBello MP, Schwiers ML, Rosenberg HL, Strakowski SM. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiat 2002; 41: 1216–23. 34. De Nayer A, Windhager E, Irmansyah F, et al. Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics. Int J Psychiat Clin Pract 2003; 7: 59–66. 35. Emsley RA, Raniwalla J, Bailey PJ et al. A comparison of the effects of quetiapine ("Seroquel") and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. Int Clin Psychopharmacol 2000; 15: 121–31. 36. Fleischhacker W, Linkz C, Hurst B. JCJ-204636 (Seroquel) – a putative new atypical antipsychotic: results from phase III trials. Schizophr Res 1996; 2/3: l32. 37. Fulton B, Goa K. JCJ-204.636. An initial appraisal of its pharmacological properties and clinical potential in the treatment of schizophrenia. CNS Drugs 1995; 1: 68–78. 38. Gefvert O, Lindstrom L, Langstrom B et al. Time course for dopamine and serotonin receptor occupancy in the brain of schizophrenic patients following dosing with 150 mg. «Seroquel» TTD. Eur Neuropsychopharmacol 1996; 6: 74. 39. Ghaemi SN, Goldberg JF, Henry CA et al. Quetiapine for rapid-cycling bipolar disorder: a long-term follow-up study (abstract). Bipolar Disord 2003; 5 (suppl 1): 50. 40. Goldstein J. Preclinical profile of Seroquel (quetiapine): an atypical antipsychotic with clozapine-like pharmacology. Schizophrenia: Breaking down the barriers. Ed. Holliday S., Ancil R. and Mac Ewan G. 1996; 177–208. 41. Goldstein J, Arvanitis L. JCJ-204, 636 (Seroquel): a dibenzothiazepine atypical antipsychotic. Review of preclinical pharmacology and highlights of phase II clinical trials. CNS Drugs Reviews 1: 50–73. 42. Goodwin GM. (Consensus Group of the British Association for Psychopharmacology): Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2003; 17: 149–73. 43. Goodwin F, Jamison K. Manic-Depressive Illness. New York, Oxford University Press 1990. 44. Harmon T, Krenzelok E. Rapid loss of consciousness from acute quetiapine overdosage. J Toxicol - Clin Toxicol 1997; 35 (5): 546. 45. Hellewell JSE, Kalali AH, Langham SJ et al. Patient satisfaction and acceptability of long-term treatment with quetiapine. Int J Psychiatry Clin Pract 1999; 3: 105–13. 46. Hirschfeld RM. The efficacy of atypical antipsychotics in bipolar disorders. J Clin Psychiat 2003; 64 (Suppl 8): 15–21. 47. Janicak PG, Davis JM, Ayd F et al. The Pharmacology of Bipolar Disorders. In: Janicak PG et al. Principles and practice of psychopharmacotherapy. Update 3. Baltimore: Williams & Wilkins., 1995. 48. Jones M, Huizar K. Practice guideline for the treatment of patients with bipolar disorders (revision). Am J Psychiat 2002; 159: 1–50. 49. Judd LL, Akiskal HS, Schettler PJ et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiat 2003; 60: 261–9. 50. Kaplan Н, Sadock B. Comprehensive Textbook of Psychiatry, 4th edn.1996. 51. Lapin IP, Oxenkrug GF. Intensification of the central serotoniner process as a possible determinant of the thymoleptic effect. Lancet 1969; 1: 132–6. 52. Link C, Arvanitis L, Miller B et al. A multicentre, placebo-controlled, double-blind evaluation of Seroquel in hospitalised patients with acute exacerbation of chronic and subchronic schizophrenia. Eur Neuropsychopharm 1994; 4 (3 Spec. Jss): 385–6. 53. Link С, Smith A, Miller В et al. A multicentre, double-blind, controlled comparison of Seroquel and chlorpromazine in the treatment of hospitalised patients with acute exacerbation of subchronic and chronic schizophrenia. Eur Neuropsychopharm 1994; 4 (3 Spec. Jss): 385. 54. McIntyre RS, Brecher M, Paulsson B et al. Quetiapine or haloperidol as monotherapy for bipolar mania—a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol 2005; 15: 573–85. 55. McManus DQ, Rak IW. Safety and Tolerability of «Seroquel» (QUETIAPINE) in Elderly Subjects with Psychosis. Neurology 1997; 48: А100. 56. Meats P. Quetiapine (Seroquel): an effective and well-tolerated atypical antipsychotic. Int J Psychiat Clin Pract 1997; 4: 231–9. 57. Mullen JA, Devine NA, Sweitzer DE. Quetiapine versus placebo as adjnct to Lithium or Divaloproex for the treatment of bipolar disorder. Presented at the Psychiatric Congress: Quetiapine and Bipolar Affective Disorders, October 14–17, 2003, Kanne, France. 58. Nudelman E, Vinuela LM, Cohen CI. Safety in Overdose of Quetiapine: A Case Report. J Clin Psychiat 1998; 59 (8): 433. 59. Paulsson B, Huizar K. Quetiapine monotherapy for treatment of bipolar disorder. Presented at the Psychiatric Congress: Quetiapine and Bipolar Affective Disorders, October 14–17, 2003, Kanne, France. 60. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiat 2002; 63: 1121–8. 61. Post RM, Leverich GS, Altshuler LL et al. An overview of recent findings of the Stanley Foundation Bipolar Network (part I). Bipolar Disord 2003; 5: 310–9. 62. Pollack PT, Zbuk K. Quetiapine fumarate overdose: clinical and pharmacokinetic lessons from extreme conditions. Clin Pharmacol Ther 2000; 68 (1): 92–7. 63. Purdon SE, Malla A, Labelle A, Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiat Neurosci 2001; 26: 137–49. 64. Robinson С, Robinson К, Castaner J. Quetiapine Fumarate. Drugs of the Future 1996; 5: 483–9. 65. Sachs G, Chengappa KN, Suppes T et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2004; 6: 213–23. 66. Sacts GS, Printz DJ, Kahn DA et al. The Expert Consensus Guide Line Series: Medication Treatment of Bipolar Disorders. Posgaded Med 2000; 1: 104. 67. Sailer C, Salama A. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology 1993; 3: 285–92. 68. Sajatovic M, Brescan DW, Periz DE et al. Quetiapine alone and added to a mood stabilizer for serious mood disorders J Clin Psychiat 2001; 62: 728–32. 69. Sajatovic M, Mullen JA, Sweitzer DE. Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J Clin Psychiat 2002; 63: 1156–63. 70. Seroquel: a putative atypical antipsychotic drug with serotonin- and dopamine-receptor antagonist properties. J Clin Psychiat 1995; 9: 438–45. 71. Shimada E, Murasaki M, Miura S et al. A phase I study in healthy volunteers of JCJ 204636, a novel neuroleptic agent. Can J Physiol Phannacol 1994; 72 (suppl.1): 445. 72. Simons WR, Bassi R, White R. Antipsychotic compliance evaluation: a population-based managed care study of persistence with initially prescribed antipsychotic medication. International Society for Pharmacoeconomics and Outcomes Research 4th Annual European Congress, Cannes, France, 11–13 November 2001. 73. Simons WR. Persistency and Compliance Evaluation (PACE): a US population-based analysis of persistency with initially prescribed antipsychotics. College of Psychiatric and Neurologic Pharmacists 6th Annual Meeting, Charleston, South Carolina, USA, 1–4 May 2003. 74. Seemuller F, Forsthoff A, Dittmann S et al. The safety and tolerability of atypical antipsychotics in bipolar disorder. Expert Opin Drug Saf 2005; 4 (5): 849–68. 75. Smith MA, McCoy R, Hamer J, Brecher M. Optimal titration for quetiapine: pilot trial. College of Psychiatric and Neurologic Pharmacists 5th Annual Meeting, Seattle, Washington, USA, 18–21 April 2002. 76. Smith MA, McCoy R, Hamer J et al. Rapid dose escalation with Quetiapine. J Clin Psychopharmacol 2005; 25: 331–35. 77. Stahl S. Psychopharmacology of antipsychotics. Martin Dunitz Ltd, London: 1999. 78. Sverdlov NR. Dopamine and depression: circuitas logic? J Biol Psychiay 1993; 33: 751–8. 79. Suppes T, McElroy SL, Keck PE et al. Use of quetiapine in bipolar disorder: a case series with prospective evaluation. Int Clin Psychopharmacol 2004; 19: 173–4. 80. Targum SD, Criden MR. Efficacy of «Seroquel» (Quetiapine) in Parkinson\'s Patients With Psychosis. Movement Disord 1997; 12 (5): 842–3. 81. Thase ME, Macfadden W, Weisler RH et al. Efficacy of Quetiapine Monotherapy in Bipolar I and II Depression. A Double-blind, Placebo-controlled Study (The BOLDER II Study). J Clin Psychopharmacol 2006; 26: 600–9. 82. Vieta E, Mullen J, Brecher M et al. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies. Curr Med Res Opin 2005; 21: 923–34. 83. Vieta E, Parramon G, Padrell E et al. Quetiapine in the treatment of rapid cycling bipolar disorder. Bipolar Disord 2002; 4: 335–40. 84. Wong Y, Ewing B, Jaskiw G et al. Multiple-doses of «Seroquel» (quetiapine) in elderly psychotic patients. 149th Annual meeting of АРА. N.Y. (May 4–9), 1996. 85. Yeang PP, Goldstein JM, Hellewell JSE. Extrapyramidal Symptoms in General and Elderly Psychotic Patients Population. Presented at the Psychiatric Congress: Quetiapine and Bipolar Affective Disorders. Kanne, France. October, 14–17 2003. 86. Zarate CA, Rothschild A, Fletcher KE et al. Clinical predictors of acute response with quetiapine in psychotic mood disorders. J Clin Psychiat 2000; 61: 185–9. 87. Zornberg GL, Pope HG. Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol 1993; 13: 397–408.